Literature DB >> 14681944

The use of fine-needle aspiration cytology and core biopsy in the assessment of highly suspicious mammographic microcalcifications: analysis of outcome for 182 lesions detected in the setting of a population-based breast cancer screening program.

Gelareh Farshid1, Gill Rush.   

Abstract

BACKGROUND: Fine-needle aspiration biopsy (FNAB) is used as the first-line diagnostic test for lesions that require morphologic assessment in the authors' breast cancer screening program. A positive cytologic diagnosis is an indication to proceed to definitive surgery. Core biopsy is used if FNAB is not diagnostic. In the context of increased use of core biopsy at other centers, the authors reviewed their experience with the cytologic assessment of highly suspicious microcalcifications.
METHODS: Between January 1996 and June 2000, the dominant radiologic abnormality was classified prospectively as high-grade microcalcifications in 182 lesions. Data were recorded on patient demographics, radiologic features, and the findings of FNAB and core biopsy, if performed. The results of the screening assessment were then compared with the final histologic findings.
RESULTS: Overall, 15.6% of all radiologically high-grade lesions were microcalcifications. The mean patient age was 58.76 years. The lesions had a mean size of 38.49 mm (range, 5-200 mm), and 92.31% of high-grade microcalcifications proved to be malignant. Among the cases evaluated by FNAB, a positive cytologic diagnosis of malignancy was made in 70.93% of lesions, without any false-positive diagnoses and obviating the need for diagnostic core biopsy. FNAB had a sensitivity of 77.22% and a positive predictive value (PPV) of 100%. When core biopsy was performed due to the absence of a positive cytologic diagnosis, it averted the need for open biopsy in 76% of lesions.
CONCLUSIONS: Where there is access to skilled cytopathologists, FNAB can provide a highly accurate, rapid, and cost-effective means of triage of patients who would benefit most from the more expensive core biopsy. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2003        PMID: 14681944     DOI: 10.1002/cncr.11785

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Image-directed fine-needle aspiration biopsy of the thyroid with safety-engineered devices.

Authors:  Randy R Sibbitt; Dennis J Palmer; Wilmer L Sibbitt; Arthur D Bankhurst
Journal:  Cardiovasc Intervent Radiol       Date:  2010-11-06       Impact factor: 2.740

2.  The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases.

Authors:  Mary F Dillon; Arnold D K Hill; Cecily M Quinn; Ann O'Doherty; Enda W McDermott; Niall O'Higgins
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

3.  Can concurrent core biopsy and fine needle aspiration biopsy improve the false negative rate of sonographically detectable breast lesions?

Authors:  Yao-Lung Kuo; Tsai-Wang Chang
Journal:  BMC Cancer       Date:  2010-07-16       Impact factor: 4.430

4.  Core biopsy as a tool in planning the management of invasive breast cancer.

Authors:  Amar Deshpande; Trivikram Garud; Simon D Holt
Journal:  World J Surg Oncol       Date:  2005-01-04       Impact factor: 2.754

5.  Ultrasound-guided large-core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumour classification.

Authors:  G Sauer; H Deissler; K Strunz; G Helms; E Remmel; K Koretz; R Terinde; R Kreienberg
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.